Humanin: A Mitochondrial-Derived Cytoprotective Peptide for Aging Research

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to humanin. Humanin is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Your mitochondria encode more than energy. In 2001, a team of Japanese researchers found something unexpected inside the 16S ribosomal RNA gene of mitochondrial DNA: a short peptide sequence that appeared capable of blocking neuronal death triggered by Alzheimer's-related proteins. It did not come from nuclear DNA. It came from within the mitochondria themselves. That discovery reframed how scientists think about what mitochondria actually do, and it opened a line of research on what are now called mitochondrial-derived peptides.

This article covers what humanin is, how it was discovered, what the cytoprotective and metabolic research shows, how it connects to IGF-1 and longevity signaling, and where the evidence currently stands. Humanin is not an available therapeutic. It is a research compound studied primarily in preclinical models, with early observational human data only.

Key Takeaways

• Regulatory Status: Not FDA-approved for human use; no Category 1 or Category 2 bulk drug substance classification; not legally marketed for human use in any formulation as of April 2026.
• Research Stage: Primarily preclinical (cell culture and rodent models); limited human observational data on circulating humanin levels; no completed human efficacy or safety trials.
• Availability: Not legally marketed for human use. Superpower does not offer this substance.
• What it is: A 24-amino-acid peptide encoded within mitochondrial DNA, studied for cytoprotective, neuroprotective, and metabolic signaling effects.
• What the evidence actually shows: Robust preclinical cytoprotection data; human data limited to observational studies showing declining circulating humanin levels with age as of April 2026. View compound reference data (PubChem CID 16198889).

Where Humanin Comes From and How It Works

Origin and discovery

Humanin was identified in 2001 by Hashimoto and colleagues at Keio University School of Medicine, published that year in two landmark papers: one in the Proceedings of the National Academy of Sciences and a mechanistic companion in Biochemical and Biophysical Research Communications. The researchers were studying neurons from the occipital lobe of an Alzheimer's patient and screening for genes that could rescue cells from death induced by familial Alzheimer's disease mutations. One sequence, cloned from surviving neurons, encoded a 24-amino-acid peptide that abolished neuronal cell death triggered by APP, PS1, and PS2 mutant genes as well as amyloid-beta (Aβ). They named it humanin. Its genomic location was immediately unusual: the sequence is encoded within the 16S ribosomal RNA gene in mitochondrial DNA, not in the nuclear genome. This places humanin in a molecularly distinct class from peptides produced by conventional nuclear gene expression.

The mitochondrial-derived peptide family

Humanin is now understood as the founding member of what researchers call mitochondrial-derived peptides (MDPs): small signaling molecules translated from mitochondrial open reading frames rather than nuclear genes. A 2015 letter by Alis, Lucia, Blesa, and Sanchis-Gomar in the Journal of Cellular Physiology summarized the role of MDPs in metabolism, placing humanin alongside MOTS-c (a metabolic signaling peptide) and the small humanin-like peptides (SHLPs 1 through 6). A subsequent 2016 paper by Cobb and colleagues in Aging (Albany NY), from the same Cohen laboratory, further characterized the family as age-dependent regulators of apoptosis, insulin sensitivity, and inflammation. MDPs challenge a longstanding view that mitochondria function purely as energy factories. They are also signaling organs that release peptides with systemic biological effects.

Proposed mechanisms of cytoprotection

Multiple mechanisms have been proposed to explain humanin's cytoprotective activity. Ying and colleagues, publishing in the Journal of Immunology in 2004, identified formylpeptide receptor-like-1 (now designated FPR2) as a G-protein-coupled receptor that humanin binds at neuronal cell surfaces — a mechanistic identification rather than a dose-response neuroprotection study; the paper does not report quantitative cell-survival magnitudes. Additional mechanisms involve intracellular pathways: humanin has been proposed to inhibit the pro-apoptotic activity of BAX (a BCL-2 family protein that promotes mitochondrial outer membrane permeabilization) and to interact with IGFBP-3. A foundational 2003 paper by Ikonen and colleagues in PNAS demonstrated that humanin binds directly to insulin-like growth factor binding protein-3 (IGFBP-3), modulating apoptotic signaling downstream of the IGF axis. These mechanisms have been characterized in cell culture and rodent models; their translation to human biology has not been confirmed in controlled clinical trials.

The S14G analog lineage

Within months of the original discovery, a structure-activity investigation by Kariya and colleagues in the Nishimoto laboratory, published in the Journal of Neuroscience Research in 2001, systematically mapped which amino acid positions in humanin were required for neuroprotective activity against Alzheimer's-relevant insults (V642I-APP, NL-APP, M146L-PS1, N141I-PS2, and amyloid-beta 1-43), identifying Cys8 and Ser14 as essential residues and the Pro3-to-Pro19 domain as the active core. That analysis produced the S14G-humanin variant (also called HNG), in which serine at position 14 is substituted with glycine. HNG demonstrated approximately 1,000-fold greater potency than native humanin in neuroprotection assays against multiple Alzheimer's-related insults. HNG and subsequent analogs (including HNGF6A, shown to dose-dependently increase glucose-stimulated insulin secretion in Sprague-Dawley rats and in isolated islets from normal and diabetic mice through K-ATP-channel-independent, glucose-metabolism-mediated effects by Kuliawat and colleagues in a 2013 FASEB Journal paper) have since been used in most of the preclinical research literature because their potency makes them more experimentally tractable. References to "humanin" in the research literature often implicitly mean an analog rather than the native 24-amino-acid sequence.

What the Research Shows

Neuroprotection in preclinical models

The neuroprotective research is the most developed area of humanin science. In cell-culture models, humanin and its analogs near-completely suppress neuronal death induced by Alzheimer's-related proteins (mutant APP, PS1, PS2) and by amyloid-beta peptides, with statistically significant rescue (p < 0.01) at concentrations ranging from 10 nM to 10 µM in the foundational paper by Hashimoto and colleagues in PNAS in 2001. Rodent studies have extended this to behavioral outcomes: a 2018 preclinical paper by Yen and colleagues in Scientific Reports from the Cohen laboratory treated 18-month-old female C57Bl/6N mice with the humanin analog HNG at 4 mg/kg by intraperitoneal injection twice weekly; after six months of dosing (rotarod at 24 months, N = 24 control vs 23 HNG) and follow-up through 28 months (Barnes maze N = 7–8/group; spontaneous alternation N = 10/group), HNG-treated mice showed statistically significant improvements (p < 0.05) in motor coordination, spatial-memory search strategy and success rate, and Y-maze spontaneous alternation behavior relative to controls; the paper reports significance but does not publish absolute latency or alternation magnitudes in the abstract. The same paper reported that circulating humanin concentrations decline with age in both mice and humans, framing the peptide as a potentially relevant signal in the biology of cognitive aging, though these findings remain preclinical — no controlled human cognitive trial of humanin or HNG has been completed. These findings are notable, but the mechanistic evidence comes predominantly from transgenic mouse models of Alzheimer's disease, which have historically not translated well to human efficacy trials. No completed human neuroprotection trial has been published as of April 2026.

Cardioprotection

A 2010 preclinical study by Muzumdar and colleagues in Arteriosclerosis, Thrombosis, and Vascular Biology examined the humanin analog HNG in a mouse model of myocardial ischemia-reperfusion (45 minutes of left coronary artery occlusion followed by 24 hours of reperfusion); acute intraperitoneal HNG administration reduced infarct size dose-dependently with maximal reduction at 2 mg/kg, mediated by AMPK–endothelial nitric oxide synthase signaling and modulation of apoptotic factors in cardiomyocytes. This is preclinical rodent evidence only — no human cardiac safety or efficacy data has been published as of April 2026.

Metabolic effects and insulin sensitization

Humanin has been studied in the context of insulin action and metabolic health. A 2009 preclinical paper by Muzumdar and colleagues in PLoS One used hyperinsulinemic-euglycemic clamps in Sprague-Dawley rats (n = 5–7 per group) and in Zucker diabetic fatty rats, showing that continuous intracerebroventricular humanin infusion at 0.16 µg/kg/min raised the glucose infusion rate and improved peripheral insulin sensitivity, an effect reproduced by intravenous administration of the HNGF6A analog; hypothalamic STAT-3 inhibition abolished the hepatic effect of peripheral HNGF6A, localizing the action to a central-nervous-system–mediated pathway, and a single HNGF6A dose significantly lowered blood glucose in Zucker diabetic fatty rats. This is preclinical rodent evidence only, and the small per-group n limits precision. A 2018 paper by Han and colleagues in the Journal of Cellular Biochemistry reported that S14G-humanin reduced hippocampal IRS-1 Ser636 phosphorylation and mTOR expression and shifted autophagy markers (increased ULK1, decreased p62, decreased LC3-I/LC3-II ratio) in APP/PS1 transgenic mice; the abstract does not disclose group sizes, dose, or magnitude of change. A comprehensive 2020 review by Merry, Chan, Woodhead, and colleagues in the American Journal of Physiology: Endocrinology and Metabolism synthesized the evidence on MDPs (humanin, MOTS-c, SHLP2) across energy metabolism, glucose regulation, and insulin sensitivity, noting that circulating MDPs are directionally lower in obesity, diabetes, and aging (specific fold-changes vary by study and are not aggregated in this review) and that — although rodent interventional data are consistent with metabolic benefit — human intervention data does not yet exist. A broader 2022 review by Boutari, Pappas, and colleagues in the World Journal of Diabetes examined humanin across in vitro and in vivo diabetes studies — directionally reporting that humanin and analogs increase insulin sensitivity, improve pancreatic beta-cell survival, and delay diabetes onset in animal models, while consistently hedging the therapeutic inferences in the absence of human trials. The review does not aggregate quantitative magnitudes across the underlying studies.

Humanin and IGF-1: the longevity signaling axis

One of the more intriguing threads in humanin research is its relationship to IGF-1 signaling, which has long been linked to aging across multiple species. A 2014 paper by Lee and colleagues in Aging Cell from the Cohen laboratory showed that IGF-I — not GH itself — regulates circulating humanin: in GH-deficient children, plasma humanin was strongly negatively correlated with IGF-I (Pearson r = −0.69, p < 0.05) but not with GH (r = −0.04, p = 0.9), and four weeks of GH replacement (which raises IGF-I) reduced plasma humanin by approximately 20%; in mice, long-lived GH-deficient Ames dwarfs had elevated humanin while short-lived GH-transgenics had reduced humanin, establishing a positive humanin–lifespan correlation across genotypes. A parallel 2014 review by Lee, Yen, and Cohen in Frontiers in Endocrinology synthesized the connections between humanin and age-related diseases including Alzheimer's, diabetes, cardiovascular disease, and stroke. This established the IGF-1/humanin axis as a research construct: reduced IGF-1 signaling (associated with longevity in some models) is inversely related to humanin levels, while humanin itself appears to promote cell survival through pathways that include IGFBP-3 interaction. The implication, studied in model organisms, is that humanin may be one molecular mechanism connecting mitochondrial function to systemic aging trajectories. This connection to IGF-1 biology is why humanin appears in the longevity peptide literature despite having no therapeutic indication.

Human observational data on circulating humanin levels

The most direct human evidence for humanin's relevance comes from observational studies measuring plasma humanin concentrations. The 2018 paper by Yen and colleagues in Scientific Reports documented that circulating humanin declines with age in humans (directional finding; abstract does not publish a quantitative % decline per decade) and identified a single-nucleotide polymorphism (rs2854128) associated with both lower circulating humanin and accelerated cognitive aging. A 2019 cross-sectional study by Conte and colleagues in the Journal of Gerontology: Biological Sciences and Medical Sciences measured FGF21, GDF15, and humanin across 693 subjects aged 21–113 years and found that all three mitokines increased with old age, with the highest levels observed in centenarians; within the oldest old, these same mitokines inversely correlated with handgrip strength and insulin sensitivity, complicating any simple interpretation that more humanin is better. A follow-up 2021 paper by Conte and colleagues in GeroScience profiled plasma humanin alongside FGF21 and GDF15 in patients with type-2 diabetes versus Alzheimer's disease versus healthy aging controls and found disease-specific patterns: GDF15 was elevated in T2D but not in AD, while FGF21 and humanin were reduced in AD but unchanged in T2D; combining GDF15 with HbA1c improved ROC-AUC for identifying T2D complications versus either marker alone (specific AUC values not reported in the abstract). These observational findings are consistent with a role for humanin in aging biology but do not establish causality, and they do not constitute evidence for therapeutic efficacy.

Regulatory and Legal Status

FDA classification

As of April 2026, humanin is not FDA-approved for any human indication. It does not appear on the FDA's Category 1 or Category 2 bulk drug substance lists, meaning it has not been evaluated for inclusion in compounded medications and has no established compounding pathway. No IND application, NDA, or BLA for humanin or its analogs has reached a publicly disclosed stage. The regulatory position is absence of any approval framework, not a specific prohibition. The practical consequence is the same: there is no legal pathway to obtain humanin as a pharmaceutical product in the United States.

What this means practically

Products labeled as humanin or humanin analogs sold through online vendors are not regulated by the FDA. There is no legally available pharmaceutical-grade humanin for human use. Independent analytical testing of research peptide markets has documented contamination, dosing inconsistency, and misidentified compounds across categories. Humanin analogs like HNG require careful manufacturing controls (specific amino acid substitutions at defined positions) that are not verifiable in unregulated online products. Purchasing and self-administering such products carries risks that are separate from and in addition to the uncharacterized safety profile of humanin itself.

Safety: What Is and Is Not Known

Absence of clinical safety data

No Phase 1 clinical safety trial for humanin or any humanin analog has been completed and published as of April 2026. The safety profile in humans is entirely unknown. Side effects, drug interactions, pharmacokinetics, and organ-level effects at any dose have not been characterized in human subjects. A 2023 comprehensive review by Coradduzza and colleagues in Biology (Basel) surveyed humanin's pathophysiological roles in aging and explicitly noted the absence of human clinical data as the primary limitation of the current evidence base. A parallel 2023 review by Karachaliou and Livaniou in Biology (Basel) covering humanin analogs in neuroprotection similarly identified the preclinical-to-translational gap as unresolved.

Risks from unregulated sources

Peptides purchased as "research use only" from online vendors are manufactured without pharmaceutical oversight, and the risk of contamination, incorrect sequence synthesis, or incorrect dosing is not theoretical. Analytical chemistry studies of the broader research peptide market have found dose and purity discrepancies. For a compound like humanin, where the specific analog (native vs. HNG vs. other variants) determines the pharmacological activity profile, purity and sequence accuracy are not cosmetic concerns.

Who Should Not Use Humanin

Based on humanin's proposed mechanisms, the following groups face elevated theoretical risk. This is not a clinical risk assessment (no human safety data exists on which to base one) but an application of mechanistic reasoning to populations where the proposed biology could create concern.

• Individuals with active or suspected malignancy: Humanin's proposed anti-apoptotic and cytoprotective mechanisms could theoretically reduce apoptotic clearance of abnormal cells, including malignant ones. This is not established in humans but is a logical concern given the compound's mechanism.
• Individuals with insulin-sensitive conditions or metabolic disorders on therapy: Humanin has shown insulin-sensitizing effects in preclinical models. Interaction with existing metabolic medications or conditions has not been studied in humans.
• Pregnant or breastfeeding individuals: No safety data exists for these populations. Given that humanin influences apoptotic regulation and potentially fetal development pathways, absence of evidence should not be interpreted as evidence of safety.
• Competitive athletes subject to WADA testing: While humanin does not currently appear by name on the WADA Prohibited List, the S0 category (non-approved substances with pharmacological activity) may apply. Athletes in tested sports should consult their sport federation and anti-doping authority before any use.
• Individuals with neurological conditions on established therapy: Humanin's neuroprotective research is closely tied to Alzheimer's disease models. Any individual managing a neurodegenerative condition should not alter established care on the basis of preclinical peptide data.

Which Biomarkers Are Relevant if You Are Exploring Peptide Science?

Humanin's proposed mechanisms engage several measurable biological systems. Understanding baseline levels in these systems provides an objective reference point before any clinical or investigational decisions are made, and these markers are informative regardless of what compound someone is exploring.

• IGF-1: The IGF-1/humanin axis is central to the longevity research literature. IGF-1 levels reflect growth hormone signaling, and the relationship between IGF-1 and circulating humanin has been characterized in multiple Cohen-laboratory studies. Understanding your IGF-1 baseline provides context for how the hormonal axis that regulates humanin production is functioning.
• hs-CRP: Humanin has been studied in the context of anti-inflammatory signaling. High-sensitivity C-reactive protein is the most widely used circulating marker of systemic inflammation and provides a baseline for evaluating any intervention or compound being explored for anti-inflammatory properties.
• Fasting insulin and HbA1c: Humanin's insulin-sensitizing effects in preclinical models make metabolic biomarkers directly relevant. Fasting insulin and hemoglobin A1c together characterize insulin resistance and glycemic status, the metabolic terrain that humanin research specifically targets.
• Glucose: As a direct measure of glycemic regulation, fasting glucose tracks the same metabolic pathway studied in humanin's central insulin-sensitization research. It provides a simple, reproducible baseline.
• Comprehensive metabolic panel: Liver and kidney function markers are standard safety markers before evaluating any investigational compound. They provide the organ-function baseline that any responsible exploration of emerging science requires.
• Comprehensive hormone panel (testosterone, DHEA-S, cortisol): Mitochondrial-derived peptides have been proposed to interact with broader hormonal aging trajectories. A hormonal baseline captures the broader endocrine context relevant to the longevity and metabolic research threads that humanin research engages.

When to Take This Seriously

The conditions that drive people toward humanin research (cognitive aging, metabolic decline, cardiovascular resilience) are real and have established clinical pathways. A neurologist, endocrinologist, cardiologist, or primary care physician can evaluate these concerns with validated diagnostic tools. Understanding your cellular aging biomarkers, metabolic baseline, and inflammatory status through bloodwork provides objective data that a provider can interpret and act on. The absence of completed human trials for humanin means that no licensed provider can translate the preclinical evidence into a defensible clinical recommendation for individual patients. Start with the biology you can measure.

That commitment to measuring first is what drives Superpower's approach to preventive health: the understanding that objective biomarker data is the foundation for every health decision, whether you are exploring established therapies or following emerging science like the mitochondrial-derived peptide literature.

IMPORTANT SAFETY INFORMATION

Humanin is NOT FDA-approved for any human indication. Superpower Health does not prescribe, sell, compound, or facilitate access to humanin or any humanin analog. This educational content is provided for informational purposes only and does not constitute medical advice, a treatment recommendation, or an endorsement of humanin for any health purpose.

No clinical safety data exists for humanin or its analogs in humans. The side effect profile, pharmacokinetics, drug interactions, and organ-level safety at any dose have not been characterized in human clinical trials as of April 2026.

Warnings: Products sold online as "research use only" humanin are not subject to FDA pharmaceutical manufacturing standards; contamination, dose inaccuracy, and misidentified compounds have been documented in the broader research peptide market. Proposed anti-apoptotic mechanisms raise theoretical concerns in individuals with active malignancy. Proposed insulin-sensitizing effects in preclinical models may interact with existing metabolic conditions or medications.

Contraindications (theoretical, based on proposed mechanisms): active or suspected malignancy; pregnancy or breastfeeding; concurrent management of insulin-dependent conditions without physician oversight; competitive athletic use subject to WADA S0 non-approved substances category.

Long-term safety data: absent. No chronic exposure data in humans exists.

This compound has no FDA-approved prescribing information. Compound reference data is available at PubChem CID 16198889.

Additional Questions

What is the S14G-humanin (HNG) analog?

HNG is a synthetic analog of native humanin in which the amino acid at position 14 is changed from serine to glycine. Kariya and colleagues characterized this substitution in 2001 in the Journal of Neuroscience Research and found it produced approximately 1,000-fold greater potency in neuroprotection assays compared to the native sequence. Most subsequent preclinical research has used HNG rather than native humanin because of this potency advantage. HNG and native humanin are distinct compounds with different potency profiles and potentially different safety considerations, though neither has human safety data.

What is the FDA peptide reclassification and does it affect humanin?

The February 2026 FDA reclassification under the Consolidated Appropriations Act addressed the bulk drug substance lists for compounded medications. Humanin was not on the Category 1 list (eligible for compounding) before the reclassification and is not on it after. Its status is unchanged: no FDA-approved formulation exists, and no compounding pathway has been established. The broader peptide reclassification primarily affected compounds that were already in clinical or compounding use.

Are peptides legal in 2026?

The legality of specific peptides varies by compound. Some peptides (such as sermorelin, bremelanotide, and tesamorelin) have FDA-approved indications or established compounding eligibility. Others, including humanin, have no approved therapeutic use and no compounding classification. The February 2026 FDA policy changes created an updated framework for which peptides can be compounded, but that framework does not create a legal pathway for compounds like humanin that were not previously eligible. Consulting a licensed healthcare provider is the appropriate step for any questions about specific compounds.